MRNA slides around 6.5% as volatility contrasts with strong momentum signals

Traders Union
All News
Stocks
Moderna drops 6.45% today

Highlights

Moderna shares saw institutional accumulation tied to Nasdaq-100 Index inclusion and advancing oncology pipeline updates with Merck.
Full-year revenue reached $1.94 billion against a net loss of $2.82 billion, with COO Juan Andres owning 125,000 shares.
Moderna stock trades in a strong uptrend above key moving averages, with forecast range of $177.07 to $201.21 and continued buying strength indicated.

Portfolio rebalancing and pipeline news drive mixed sentiment

Moderna was recently added to the Nasdaq-100 Index, resulting in institutional portfolio rebalancing and increased share accumulation ahead of the effective date. Sentiment was influenced by developments in the oncology pipeline, including a personalized mRNA cancer vaccine in partnership with Merck, with Phase 3 melanoma vaccine trial data scheduled for presentation at a major European congress. The company also reported annual revenue of $1.94 billion, a net loss of $2.82 billion, and disclosed Chief Operating Officer Juan Andres's direct ownership of 125,000 shares, though price action has remained under broader selling pressure.

Anton Kharitonov notes Moderna’s sharp 6.45% drop signals underlying volatility despite strong technical momentum. He highlights that price remains above major moving averages and momentum indicators are positive, but the notable downside gap and heavy selling pressure suggest instability. The recent bullish news, including inclusion in the Nasdaq-100 and oncology pipeline optimism, has failed to support price action in the near term. Kharitonov points to the company’s net loss and founder-level ownership as fundamental concerns amid ongoing institutional repositioning. "A single session of such strong selling raises red flags — short-term upside is capped unless buyers decisively reclaim control above $201.21," he warns.

Viktoras Karapetjanc sees the recent decline as an aberration within a strong bullish structure. He believes Moderna’s addition to the Nasdaq-100 and imminent Phase 3 data keep investor optimism intact. The current setup presents strong technical momentum and active institutional involvement, setting the stage for further growth. Karapetjanc notes buyers remain in control with clear support and upside targets visible. "This pullback offers new entry points — the bullish foundation remains strong and upward continuation is likely," he says.

Sholanke Dele sees today’s drop exposing fragility in Moderna’s share price. He stresses that even strong momentum and recent positive headlines could not halt the selloff. Dele cautions that market sentiment may quickly reverse if support at $187.69 fails. "Institutional optimism is not enough when volatility spikes — capital protection should be the priority here," he states.

Intraday volatility contrasts with firm bullish technical signals

Moderna is currently trading above the 20-day ($170.58), 50-day ($126.64), and 200-day ($69.26) moving averages, showing a strong bullish technical structure across all key timeframes. The Ichimoku Kijun at $169.56 lends further support, with the nearest support at $187.69 and resistance at $201.21. Momentum readings remain robust: MACD and ADX project continued buying strength, while RSI at 70.71 and Stochastic RSI at 62.5 are firmly in buying territory. The CCI stands at 84.74, also indicating a buy signal. Bull/Bear Power at 20.95 reveals clear dominance by buyers in intraday momentum. However, today’s session witnessed a sharp 6.45% drop to $190.11, following an opening downside gap of $1.08 (0.53%), with the stock moving near the session low and notable intraday volatility of 13.05%. This contrasts with recent momentum signals and highlights a counter-move against the generally bullish trend.

Previously it was reported that analysts downgraded Moderna due to concerns about overvaluation despite strong technical momentum and positive developments in its oncology pipeline. The current downside spike, contrasting with bullish technicals and heightened volatility, presents a pivotal moment with $201.21 as the key resistance to watch for renewed upside.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.